- BridgeBio Pharma (BBIO, Financial) to present new findings at the Heart Failure 2025 conference in Serbia.
- Focus on acoramidis for treating transthyretin amyloid cardiomyopathy (ATTR-CM).
- Key topics include clinical outcomes, quality of life, and lower incidence of atrial fibrillation events.
BridgeBio Pharma, Inc. (BBIO), a biopharmaceutical company specializing in genetic diseases, is set to present significant findings from their ATTRibute-CM study at the upcoming Heart Failure 2025 conference, which will be held in Belgrade, Serbia from May 17 to 20, 2025. The company will showcase multiple studies concerning the use of acoramidis, a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM).
Key presentations will cover various aspects such as clinical outcomes and quality of life measures for patients with variant ATTR-CM using acoramidis. One of the highlighted findings is a post-hoc analysis that demonstrates a lower incidence of atrial fibrillation events in patients. Additional data on serum TTR levels in both wild-type and variant ATTR-CM patients will also be shared.
The presentations will feature research conducted by distinguished medical institutions, including University College London, Stanford University, and the University of Montreal. Noteworthy contributors such as Dr. Anique Ducharme from the University of Montreal and Dr. Marianna Fontana from University College London, among others, will present these findings.
This event marks a significant opportunity for BridgeBio (BBIO, Financial) to share its latest advancements in genetic medicine and its commitment to improving patient outcomes in the treatment of ATTR-CM. More details about the company's efforts and research can be found on their official website.
